drugset / Trial / NCT06728189
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors
Phase 1
Recruiting
13 enrolled
Peking University Cancer Hospital & Institute
Suzhou Cure Genetics Biosciences Co., Limited. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced malignant solid tumors. Condition or disease：advanced malignant solid tumors Intervention/treatment：Biological: CD70 CAR-NKT cells Phase：Phase 1
Timeline
- Start
- 2024-11-14
- Primary completion
- 2026-10-17
- Completion
- 2026-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CGC738 | Cell therapy | 5e+06 unknown | Other |
| Subject | CGC738 | Cell therapy | 1.5e+07 unknown | Other |
| Subject | CGC738 | Cell therapy | 4.5e+07 unknown | Other |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |